Arthritis News and Research

Latest Arthritis News and Research

Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results of additional analyses from the phase III clinical trials of OTEZLA, the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4).

11 Jun 2014

Researchers find standard heart disease risk assessment tools for rheumatoid arthritis patients

Rheumatoid arthritis patients overall are twice as likely as the average person to develop heart problems. Pinpointing which rheumatoid arthritis patients need stepped-up heart disease prevention efforts has been a challenge; research by Mayo Clinic and others has found that standard heart disease risk assessment tools may underrate the danger a particular person faces.

11 Jun 2014

AbbVie's ALIGN study underscores patients’ attitudes and adherence toward TNF inhibitors

AbbVie today announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases (IMIDs), adherence to treatment was generally higher in patients being treated with TNF inhibitors compared to patients treated with conventional therapy.

11 Jun 2014

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that Bayer HealthCare has submitted an application to the European Medicines Agency (EMA) seeking marketing authorization in the European Union (EU) for EYLEA (aflibercept) Injection for the treatment of macular edema following branch retinal vein occlusion (BRVO).

11 Jun 2014

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today new pre-clinical results with its Development Candidate (DC) for ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 in development for the treatment of complement-mediated diseases.

10 Jun 2014

Advances in understanding of genetics of CAD lead to more therapeutic targets

Advances in the understanding of the genetics of coronary artery disease, or CAD, will revitalize the field and lead to more therapeutic targets for new medicines to combat this common disease, suggests a genetics expert from the Perelman School of Medicine at the University of Pennsylvania in a Perspective article in the new issue of Science Translational Medicine.

9 Jun 2014

NASA astronaut to give presentation at NIH in Bethesda, Maryland

NASA astronaut Mike Hopkins, recently returned from living and working aboard the International Space Station, will give an open-media, presentation Tuesday, June 10, at the National Institutes of Health (NIH) in Bethesda, Maryland.

9 Jun 2014

Viewpoints: Tea party missing the lesson; health care not an ordinary market; Va.'s Medicaid battle

But the Tea Party does have something to show for its five years of annoyance: Ted Cruz, senator from Texas. Cruz is probably best known for reading "Green Eggs and Ham" on the floor of the Senate during a 21-hour talkathon designed to ensure his place as the most hated man in that august chamber.

9 Jun 2014

TSRI develops accurate structural map of complex molecular machines in cells

A team led by researchers at The Scripps Research Institute (TSRI) has used advanced electron microscopy techniques to determine the first accurate structural map of Mediator, one of the largest and most complex "molecular machines" in cells.

6 Jun 2014

ImStem successfully treats animal model of multiple sclerosis using hESC

ImStem Biotechnology, Inc. (ImStem) announced today it has successfully treated an animal model of multiple sclerosis (MS) using human embryonic stem cells (hESC) derived mesenchymal stem cells (MSCs), called hES-MSCs.

6 Jun 2014

Glenmark Pharmaceuticals opens new monoclonal antibody manufacturing facility in Switzerland

Glenmark Pharmaceuticals S.A (GPSA), a wholly-owned subsidiary of Glenmark Pharmaceuticals Limited, India (GPL), announced the opening of its new cGMP compliant monoclonal antibody manufacturing facility in La Chaux-de-Fonds, Switzerland. T

4 Jun 2014

Medicare to pay for hep C screenings for baby boomers

The decision comes amid controversy surrounding the costs of new drugs to treat the blood-borne virus. Meanwhile, two studies find that Medicare could save billions if doctors switched from an expensive eye medication to a similar, much cheaper one and, also, if Part D plans were selected based on the actual drugs patients take.

4 Jun 2014

Polyarticular juvenile idiopathic arthritis (PJIA): an interview with Dr. Kramer, VP, Immunology and Infectious Diseases Medical Unit, Genentech

Polyarticular Juvenile Idiopathic Arthritis (PJIA) is a type of Juvenile Idiopathic Arthritis (JIA), a group of Rheumatoid Arthritis (RA) diseases that manifests in multiple ways in children.

3 Jun 2014

Study uncovers marijuana's potential to treat autoimmune diseases

A team of University of South Carolina researchers led by Mitzi Nagarkatti, Prakash Nagarkatti and Xiaoming Yang have discovered a novel pathway through which marijuana can suppress the body's immune functions. Their research has been published online in the Journal of Biological Chemistry.

3 Jun 2014

FDA approves Can-Fite's study protocol for CF102 Phase II clinical trial for advanced liver cancer

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the U.S. FDA has agreed with the Company's study protocol for its Phase II clinical trial of CF102 for the treatment of advanced liver cancer.

2 Jun 2014

$Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma$

Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

Nektar Therapeutics announced today new data from an investigator-sponsored Phase 2 study of NKTR-102 (etirinotecan pegol) in patients with Avastin-refractory high-grade glioma conducted at Stanford Cancer Institute under the direction of Lawrence Recht, M.D., Professor of Neurology and Neurosurgery, with co-investigator Seema Nagpal, M.D., Clinical Assistant Professor of Neurology and Neurological Sciences, Stanford School of Medicine.

2 Jun 2014

Arthritis News and Research

Latest Arthritis News and Research

Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

Researchers find standard heart disease risk assessment tools for rheumatoid arthritis patients

AbbVie's ALIGN study underscores patients’ attitudes and adherence toward TNF inhibitors

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Advances in understanding of genetics of CAD lead to more therapeutic targets

NASA astronaut to give presentation at NIH in Bethesda, Maryland

Viewpoints: Tea party missing the lesson; health care not an ordinary market; Va.'s Medicaid battle

TSRI develops accurate structural map of complex molecular machines in cells

ImStem successfully treats animal model of multiple sclerosis using hESC

Glenmark Pharmaceuticals opens new monoclonal antibody manufacturing facility in Switzerland

Medicare to pay for hep C screenings for baby boomers

Polyarticular juvenile idiopathic arthritis (PJIA): an interview with Dr. Kramer, VP, Immunology and Infectious Diseases Medical Unit, Genentech

Study uncovers marijuana's potential to treat autoimmune diseases

FDA approves Can-Fite's study protocol for CF102 Phase II clinical trial for advanced liver cancer

Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

MediNatura to purchase Heel Group's USA operation

WHO member states recognize psoriasis as chronic, non-communicable disease

Inovio announces positive results on DNA-based monoclonal antibody therapy targeting CHIKV

TSRI researchers discover key proteins involved in one type of DNA repair gone awry

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Arthritis News and Research

Latest Arthritis News and Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in